1. Home
  2. UEIC vs SCYX Comparison

UEIC vs SCYX Comparison

Compare UEIC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$4.31

Market Cap

60.6M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.45

Market Cap

51.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
SCYX
Founded
1986
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.6M
51.1M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
UEIC
SCYX
Price
$4.31
$5.45
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$3.50
$3.00
AVG Volume (30 Days)
97.9K
253.6K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
23.78
61.36
EPS
N/A
N/A
Revenue
$368,288,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$0.57
52 Week High
$5.99
$6.09

Technical Indicators

Market Signals
Indicator
UEIC
SCYX
Relative Strength Index (RSI) 38.77 62.02
Support Level $3.87 $0.65
Resistance Level $4.43 $5.56
Average True Range (ATR) 0.33 0.39
MACD -0.11 0.01
Stochastic Oscillator 4.35 56.25

Price Performance

Historical Comparison
UEIC
SCYX

About UEIC Universal Electronics Inc.

Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: